Evaluation Using Intragen Fractional Radiofrequency With NeuViVa for the Treatment of Vaginal Laxity and Urogynecology Symptoms.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03280446|
Recruitment Status : Unknown
Verified March 2018 by SHERRY Thomas, The American Association of Female Pelvic Medicine Specialists, Inc..
Recruitment status was: Recruiting
First Posted : September 12, 2017
Last Update Posted : March 23, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Vaginal Laxity Urinary Incontinence Sexual Dysfunction||Device: Intragen fractional radiofrequency with NeuViVa||Not Applicable|
A total of thirty (30) subjects will be enrolled and assigned to a single treatment arm, receiving active treatment clinic, with the visits consisting of three (3) treatment administrations and post-procedure visits days 30, 180 and 360. Pre-menopausal and post-menopausal women between ages over 18, vaginal delivery, with up to moderate pelvic prolapse 2 cm past the hymen, and self-reported vaginal laxity score of "very loose", moderately loose", or "slightly loose" as defined by theVaginal Laxity Questionnaire (VLQ) will be evaluated and enrolled after having met all inclusion and exclusion criteria.
The treatment administration phase will consist of three (3) treatments,delivered approximately on-month apart. Subjects will be placed on the treatment table in the dorsal lithotomy position. The monopolar return pad will be placed on the subject buttock and to the RF generator.Coupling fluid will be used as a lubricant and will be reapplied throughout the treatment as needed. The treatment area is approximately 20+ cm2 and consist of the outside perineum and entire vaginal circumference along the length of the vagina to include the apex. For treatment of the labia majora, the treatment tip will be applied across the entire anatomical region. The treatment tip is applied to the perineum bilaterally from the lowest edge of the mons pubis to the perineal body and laterally to the crural folds to achieve vulvar and perineal temperatures of between 40-45 degrees celsius for approximately 5 minutes or more of total heat time per area. The labia majora and perineal areas will take approximately 10-15 minutes to complete. This is followed by treating the epithelial surface of the vaginal opening and advancing to the length of the vaginal canal with the treatment occurring along the vaginal walls, floor, and ceiling. The entire vaginal area will be treated in a circumferential area by delivering the RF in a systematic fashion at 5 separate delivery position starting the most distal portion of the vagina. The probe is slowly retracted at 1 cm intervals and circumferentially delivered again at 5 positions on another circumferentially manner moving the probe clockwise or counter clockwise or counter clockwise. To include the entire length of the urethra and bladder will be included in the treatment. Total vaginal treatment time will be 15-20 minutes. Safety measures will include monitoring of adverse events including pain or burns or infections during and after the procedure. Evaluations will be conducted with the visits at days 30, 90 and 150 days post-procedure.
During and after treatment administration, subjects will be asked to assess the self- reported pain experience using a 10 scale VAS, with "0" being no pain and "10" being the worst pain imaginable. Descriptive statistics will be generated on all demographic, medical history, and physical examination findings including means and standard deviations, for continuous, and frequencies and percentages for categorical variables.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation Using Intragen Fractional Radiofrequency With NeuViVa for the Treatment of Vaginal Laxity and Urogynecology Symptoms.|
|Actual Study Start Date :||August 23, 2017|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||August 2019|
Experimental: 30 pre-menopause and post-menopause women
Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
Device: Intragen fractional radiofrequency with NeuViVa
The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
- To evaluate the efficacy of transcutaneous Fractional Radiofrequency Device (TFRF) for the treatment of vaginal laxity using the vaginal laxity questionnaire (VLQ). [ Time Frame: 12 month ]The primary outcome measure is the mean change in the severity of the vaginal Laxity (VL) and in female Sexual Function Inventory (FSFI) by using VLQ, assessment and visual analog scale compared to base line.
- To evaluate the efficacy of transcutaneous Fractional Radiofrequency Device (TFRF) for the treatment of urogynecological symptoms. [ Time Frame: 12 month ]To seasures improvement in subject sexual satisfaction and Urogynecological symptoms using sexual satisfaction Questionnaire (SSQ) and GRA (Global Response Assessment)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||Yes|
Healthy female adult subjects presenting, clinically, with VL, and has expressed interest in treatment will be considered eligible for the study. Enrollment of subject will depend on meeting the following criteria:
- Voluntarily signed informed consent form
- Ages ≥ 18
- Completed urine pregnancy examination with negative result if premenopausal
- Self-reported perceptions of vaginal laxity deﬁned as "very loose," "moderately loose," or slightly loose" on the Vaginal Laxity Questionnaire.
- Up to Baden-Walker Grade 2 or Stage 2 Pelvic Organ Prolapse (≤ 1 cm past hymen)
- Papanicolaou smear cytology within 36 months prior to treatment showing no dysplasia
- Subject willing to take valacyclovir at 100 mg PO q12h x 3 for history recurrent episode of HSV
- or 1000mg PO q daily x 5 days
Baden-Walker System Severe pelvic prolapse (≥ Stage 3); Pelvic organ prolapse up to
1 cm beyond the hymenal ring.
- Active STD (e.g. genital herpes, condylomata)
- Body mass index ≥ 35
- Previous reconstructive vaginal surgery, vaginal lasers, or vaginal injections of fat or fillers within 6 months.
- Current urinary tract infection
- Actively participating in, or planning on participating in, pelvic floor muscle strengthening exercises.
- Presence of pacemaker, AICD, or other electrical health maintenance device.
- Immunosuppression (pathological or medication induced, such as steroids, methotrexate) inﬂammatory drugs on a chronic basis (e.g., ibuprofen, aspirin and steroids) that can affect collagen or healing. Subject may qualify if willingly fulﬁlls a 30-day washout period of such drugs prior to treatment.They were using anti-inﬂammatory drugs on a chronic basis (e.g., ibuprofen, aspirin and steroids) that can affect collagen or healing. Subject may qualify if willingly fulﬁlls a 30 days washout period of such drugs prior to treatment.
Those with clinically signiﬁcant anxiety or depression that may prohibit completion of treatments and/or suffering a medical problem that might interfere with wound healing.
• All subjects on oral contraceptives prior to enrollment are encouraged to take these throughout the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03280446
|Contact: Sherry Thomas, MDemail@example.com|
|United States, California|
|The American Association of Female Pelvic Medicine Specialists, Inc.||Recruiting|
|Agoura Hills, California, United States, 91301|
|Contact: Sherry Thomas, MD 818-991-0988 firstname.lastname@example.org|
|Contact: Sharan Dhaliwal 8189910988|
|Principal Investigator: Sherry Thomas, MD|
|Responsible Party:||SHERRY Thomas, Sherry Thomas, MD, MPH, The American Association of Female Pelvic Medicine Specialists, Inc.|
|Other Study ID Numbers:||
|First Posted:||September 12, 2017 Key Record Dates|
|Last Update Posted:||March 23, 2018|
|Last Verified:||March 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Product Manufactured in and Exported from the U.S.:||Yes|
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Male Urogenital Diseases
Lower Urinary Tract Symptoms